49 MOST INNOVATIVE OHIO BASED ARTIFICIAL INTELLIGENCE COMPANIES
Futurology.com News (October 1, 2021) This article showcases our top picks for the best Ohio-based Artificial Intelligence companies. These startups and companies are taking a variety of approaches to innovate the Artificial Intelligence industry, but are all exceptional companies well worth a follow.
Continue Reading60 BEST OHIO ARTIFICIAL INTELLIGENCE COMPANIES AND STARTUPS
BestStartup.us News (October 1, 2021) This article showcases our top picks for the best Ohio-based Artificial Intelligence companies. These startups and companies are taking a variety of approaches to innovate the Artificial Intelligence industry, but are all exceptional companies well worth a follow.
Continue ReadingBIOSORTIA PHARMACEUTICALS NAMED LEADING PHARMACEUTICAL COMPANIES TO WATCH IN DECEMBER 2019 BY INSIGHTSCARE MAGAZINE
InsightsCare Magazine (December 29, 2019) “Biosortia Pharmaceuticals, which is on a mission to unlock the next frontier of chemistry for discovering new, groundbreaking drugs by enabling unprecedented access to microbiome chemistry”
Continue ReadingDr. John Ryals added to the Biosortia Pharmaceutical Board of Directors
San Diego, California (September 10, 2019)/PRNewswire/ – Biosortia, a leader in the next frontier of drug discovery, accessing the enormous chemical and genomic potential of natural microbiomes, is pleased to announce the addition of leading metabolomics expert, Dr. John Ryals to the Board of Directors. “It is an honor to have Dr. Ryals join the Board
Continue ReadingMicrocystins Containing Doubly Homologated Tyrosine Residues from a Microcystis aeruginosa Bloom: Structures and Cytotoxicity
American Chemical Society and American Society of Pharmacognosy (May 30, 2018) Four new microcystin congeners are described including the first three examples of microcystins containing the rare doubly homologated tyrosine residue 2-amino-5-(4-hydroxyphenyl)pentanoic acid (Ahppa) (1–4). Large-scale harvesting and biomass processing allowed the isolation of substantial quantities of these compounds, thus enabling complete structure determination
Continue ReadingLEIDOS AND BIOSORTIA PHARMACEUTICALS EXECUTE MEMORANDUM OF UNDERSTANDING
RESTON, VA (Aug. 14, 2017) – Leidos (LDOS) (NYSE: LDOS), a FORTUNE 500 science and technology company, has signed a Memorandum of Understanding (MOU) with Biosortia Pharmaceuticals to explore creating a new business relationship with a focus on identifying and advancing immuno-oncology and other immunotherapeutic opportunities.
Continue ReadingReduce Risks and Increase Revenues by Building Platforms
Columbus, OH (May 16, 2016) – Ross Youngs is the person behind the US Department of Energy R&D project that led to the development of Biosortia’s drug discovery platform. The platform can identify useful drug-like chemicals from microorganisms in water continuously. It is a way to continuously assay different microorganisms and keep finding more and more
Continue ReadingBiosortia Pharmaceuticals Announces Three New Oncology Research Projects Using Microalgal Compounds
Columbus, OH (April 26, 2016) – Biosortia Pharmaceuticals has launched three new oncology research projects. The projects will investigate Biosortia’s unique libraries of consortia microbial compounds for potential drug discovery in pediatric cancer (neuroblastoma), liver cancer (Hepatitis C virus), and an alternative approach to combat tumor growth by stimulating a patient’s immune responses (immuno-oncology).
Continue ReadingBiosortia Pharmaceuticals Introduction JLABS – San Diego
San Diego, California (February 25, 2016) – A brief explanation of what Biosortia does, how is it achieved, and why it is meaningful. Drug discovery directly from the chemistry of unculturable aquatic microorganisms in situ. ### About Biosortia Pharmaceuticals – Biosortia has a proven and unique ability to obtain unculturable aquatic microbial consortia from the natural environment in
Continue ReadingJOHNSON & JOHNSON INNOVATION INVITES BIOSORTIA PHARMACEUTICALS INTO JLABS SAN DIEGO
Biosortia Pharmaceuticals moves its corporate headquarters to biopharma hub in San Diego, California San Diego, California (January 11, 2016) – Biosortia Pharmaceuticals Inc. announces today that it has been selected by Johnson & Johnson Innovation – JLABS (JLABS) to operate as a resident company within its flagship JLABS facility in San Diego. Biosortia, a leader in
Continue Reading